Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
about
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesEffectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisEfficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysisMaintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabPredictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.Medical Treatment of Ankylosing SpondylitisThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsEmerging drugs for axial spondyloarthritis including ankylosing spondylitis.Treatment challenges in axial spondylarthritis and future directions.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Biological therapies for spondyloarthritis.Anti-TNFs in axial spondyloarthritis.Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.Efficacy and safety of adalimumab in ankylosing spondylitis.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyBrief Report: Nonsteroidal Antiinflammatory Drug-Sparing Effect of Tumor Necrosis Factor Inhibitors in Early Axial Spondyloarthritis: Results From the DESIR Cohort.[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].Axial spondyloarthritis: is there a treatment of choice?Opinion: Perspectives on imaging in axial spondyloarthritis.Adalimumab: in non-radiographic axial spondyloarthritis.Recommendations for the management and treatment of ankylosing spondylitis.Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria.Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.Natural course of bone marrow oedema on magnetic resonance imaging of the sacroiliac joints in patients with early inflammatory back pain: a 2-year follow-up study.Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].
P2860
Q26777084-B41514D2-9456-4765-8FE8-BA5FBA08426BQ26991673-7658C4E1-A706-46B9-BDB4-499F712B7722Q30776497-33C879B9-11F0-497C-AA70-051914690004Q33563272-830E01CD-DF66-4503-9E5F-3351B8FA2A21Q35608168-2B99C1DF-757E-495D-8724-1AB9A186AB3BQ35759171-4E7A45A8-9B0D-4681-9EBA-A53019309265Q36182383-A0C30B27-93A7-4546-8CEF-09FE2A5B9221Q37147133-6BC8A7DB-4CC7-4CB6-859A-CD325ABF369EQ37301134-67A9EFDC-1A75-43D7-9BB8-D34219911DF5Q38068578-71D964AA-0C20-41B3-B264-893E39D9B362Q38124281-2095D414-6797-45DA-A14F-AFF7C1DC0253Q38145501-7909B575-038F-4012-B34F-808635A83B34Q38217223-8651E12A-DC41-45A4-9CF8-8CB5CDD6FD2BQ38311916-89804807-C1EE-4F40-8C8F-0341149C1C69Q38968166-ED6103C6-700A-4E1F-86AF-A2A57779963FQ38993324-0AFAE863-52D2-4B23-BDA8-C28CF8A70F34Q39085876-4AC49D35-8C98-4E7B-89ED-7EA3485270AAQ39328197-ECB71C2C-0703-466B-942D-FA911C613C9EQ39477446-C81A56EF-C7EE-473B-958D-164895E48BA8Q40799172-37A5D5C5-320B-49CE-8047-BD5E6A336991Q41176187-E8BC20D3-2621-40D0-9C6F-9D03BF4C60BBQ42013856-057A79BE-41C1-4D2A-8197-E380977BF0D5Q42604065-1D53CD0C-934B-433A-9CD4-1704FEC9640EQ42680443-7A63A639-8482-4B84-98D5-BE92DD35C916Q44898441-52A48FAB-423D-4B20-8C10-0A3AE7128B6FQ44915013-AEB959B5-1DA9-4059-A337-2FB77F94B1DBQ48653605-5D6821FD-9CDE-4191-93C1-878EA83A02CBQ51055393-FE6C81A5-0FE2-48C8-B86B-9FC78CDB8EDDQ51257536-7B737A10-5593-4B05-A14F-23BDA3203084Q52807790-701D289B-3A92-4C7C-A3FF-2D7E2E71E423Q52874129-71BE91F3-2C23-4EF5-8358-FB3BA450FB53
P2860
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Early response to adalimumab p ...... s with ankylosing spondylitis.
@ast
Early response to adalimumab p ...... s with ankylosing spondylitis.
@en
type
label
Early response to adalimumab p ...... s with ankylosing spondylitis.
@ast
Early response to adalimumab p ...... s with ankylosing spondylitis.
@en
prefLabel
Early response to adalimumab p ...... s with ankylosing spondylitis.
@ast
Early response to adalimumab p ...... s with ankylosing spondylitis.
@en
P2093
P2860
P1476
Early response to adalimumab p ...... s with ankylosing spondylitis.
@en
P2093
Aileen L Pangan
Frederic Lavie
Joachim Sieper
L Steve Brown
P2860
P304
P356
10.1136/ANNRHEUMDIS-2011-200358
P407
P577
2011-11-29T00:00:00Z